Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor. (June 2023)

• Record Type: Journal Article
• Authors: Schepers, Allison J; Smith, David C; McDevitt, Rachel L
• Is Part Of: Journal of oncology pharmacy practice. Volume 29:Number 4(2023)
• Page Start: 912
• Page End: 916
• Publication Date: 2023-06
• Subjects: Germ cell tumor -- outpatient -- ifosfamide -- outmigration; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552231165243
• Languages: English
• ISSNs: 1078-1552

Abstract

Purpose: The combination of paclitaxel, ifosfamide, and cisplatin (TIP) is frequently used for the treatment of metastatic germ cell tumors. Due to complex supportive care and infusion requirements, TIP is typically given in the inpatient setting. This analysis describes the development and implementation of a protocol for complete outpatient administration of TIP chemotherapy. Methods: From July 2020 to June 2021, adults receiving TIP for germ cell tumor at University of Michigan Rogel Cancer Center were evaluated for outpatient administration. The primary outcome was number of inpatient bed days saved by giving outpatient TIP chemotherapy, with the goal of giving 75% of TIP cycles outpatient. Patients receiving outpatient TIP were also assessed for chemotherapy dose reduction or delays and acute toxicities of kidney injury, encephalopathy, and hemorrhagic cystitis. Results: From July 2020 to July 2021, three patients received 13 cycles of TIP. Ten cycles (77%) were administered in the outpatient setting, resulting in a savings of 50 inpatient bed days in one year. No patients required a dose reduction or delay in chemotherapy or experienced acute kidney injury, encephalopathy, or hemorrhagic cystitis during outpatient TIP treatment. Conclusion: Despite logistic and supportive care challenges, TIP can be administered completely in the outpatient setting.